Delivery Order SPE2DB20D2014-SPE2DB25FD15X
- Not listed
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packages (30-count) on September 18, 2025, with completion scheduled for October 9, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (30-count unit dose packaging) with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract is classified as a non-set-aside and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,846.97 on July 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a completion deadline of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). This firm fixed-price delivery order, valued at $13,846.97, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $27,693.94 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packages (30-count) on September 11, 2025, with an ultimate completion date of October 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The vendor, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (unit dose, 30-count packages) on September 11, 2025, with an ultimate completion date of October 2, 2025. This non-set-aside competitive award represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December...
- The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (30-count unit dose packaging) on September 8, 2025, with completion targeted for September 29, 2025. This non-set-aside contract was competitively awarded and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a firm fixed price structure. The contract, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 30, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Vyndamax 61 mg capsules (unit dose, 30-count packages) with a ceiling value of $55,387.88. This is a firm fixed price delivery order with an ultimate completion date of June 24, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location....
- The Defense Logistics Agency awarded a $27,693.94 delivery order to AmerisourceBergen Drug Corp for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by June 13, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order. The delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FD15XDelivery Order
The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (unit dose, 30-count packages) on September 26, 2025, with completion targeted for October 20, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceuticals and medical supplies to military healthcare programs globally. AmerisourceBergen Drug Corp serves as a critical vendor in the federal medical procurement supply chain, with an extensive portfolio of pharmaceutical deliveries predominantly supporting the Defense Logistics Agency and Defense Health Agency. The company's federal contract awards demonstrate capability across diverse therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies. This particular award for Vyndamax—a medication used in the treatment of transthyretin amyloidosis—exemplifies the company's role in supplying specialized pharmaceutical products to support military and veteran healthcare systems through firm fixed-price delivery mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.8k | 9/26/25 |